Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

Hypertension can be controlled adequately with existing drugs such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

Nevertheless, treatment success is often restricted by patients not adhering to treatment.

Who Took Part

The study group was 72 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, women only.

In this multicentre, double-blind, randomised, placebo-controlled phase IIa trial, 72 patients with mild-to-moderate hypertension were randomly assigned with a computer-generated randomisation list to receive subcutaneous injections of either 100 mug CYT006-AngQb (n=24), 300 mug CYT006-AngQb (24), or placebo (24), at weeks 0, 4, and 12. 24-h ambulatory blood pressure was measured before treatment and at week 14.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

Running at several centres spread the Angiotensin II study over different clinics and patient groups.

The primary outcomes were safety and tolerability.

Analyses were done by intention to treat.

This study is registered with ClinicalTrials.gov, number NCT00500786.

What Was Measured

PubMed files the paper under topics including Angiotensin II, Antibody Formation, Blood Pressure, Hypertension, Monitoring, Ambulatory, Oligopeptides and Vaccines, Synthetic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 72 patients in people with low blood pressure and orthostatic hypotension.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Lancet (London, England)), a journal based in England.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.